 |
|
|
|
 |
 |
Investigator |
 |
Institution |
 |
Project |
 |
|
Tom Curran, PhD |
|
St. Jude Children's
Research Hospital
|
|
Use of a novel SHH pathway inhibitor in human medulloblastoma
|
 |
|
Russell Matthews, PhD |
|
Yale University
|
|
Targeting a glioma-specific isoform of BEHAB/brevican for glioma therapy
|
 |
|
William Pardridge, MD |
|
University of California
Los Angeles
|
|
Non-viral polygenic gene therapy of brain cancer
|
 |
|
Paul Mischel, MD |
|
University of California
Los Angeles
|
|
Molecular analysis of glioblastoma for kinase inhibitor therapy
|
 |
 |
|
John Reed, MD, PhD
|
|
The Burnham Institute
|
|
IAP antagonists for glioblastoma
|
 |
|
Jeremy Rich, MD
|
|
Duke University
|
|
Targeting non-mitogenic receptor kinases and intracellular
mediators in glioma therapy
|
 |
|
Rosalind Segal, MD, PhD
|
|
Dana-Farber Cancer
Institute
|
|
Therapeutic use of CXCR4 antagonists in glioblastoma
|
 |
|
Paul Workman, PhD
|
|
Institute of Cancer Research UK
|
|
Mechanism of action of novel phosphatidylinositol 3-kinase
inhibitors for use in glioblastoma therapy
|
 |
|
Margaret Wrensch, PhD
|
|
University of California
San Francisco
|
|
Evaluation of SNPs from whole genome scans in relation to glioma prognosis
|
 |
|
 |
|
|
|
 |